Cathie Wood Bio Line Rx Ltd. Transaction History

Ark Investment Management LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 19, 2022	SELL	$1.46 - $2.18 $1.55 Million - $2.31 Million	-1,059,722 Closed	0 $0
Q4 2021 Jan 28, 2022	SELL	$1.98 - $3.06 $28,098 - $43,424	-14,191 Reduced 1.32%	1,059,722 $2.16 Million
Q3 2021 Nov 12, 2021	BUY	$2.65 - $3.35 $2.85 Million - $3.6 Million	1,073,913 New	1,073,913 $2.95 Million

3.35M

46.5K

6.3K

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $12.3M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

Get notified when there are updates to the investment portfolio of Ark Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on Ark Investment Management LLC and Cathie Wood with notifications on news.